(Q38045474)

27 August 2017

title

Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis? (English)

1 reference

27 August 2017

1 reference

Nils Welsh

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

24 September 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

published in

1 reference

27 August 2017

volume

21

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

1743-1750

1 reference

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

21 January 2018

Autoinhibition of c-Abl

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Aph2, a protein with a zf-DHHC motif, interacts with c-Abl and has pro-apoptotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Role of platelet-derived growth factors in physiology and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Glucose-induced phosphatidylinositol 3-kinase and mitogen-activated protein kinase-dependent upregulation of the platelet-derived growth factor-beta receptor potentiates vascular smooth muscle cell chemotaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Platelet-derived growth factor receptor-beta (PDGFR-beta) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

IRS1-independent defects define major nodes of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib attenuates diabetes-associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Stem cell factor and its receptor c-Kit as targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Sensing extracellular matrix: an update on discoidin domain receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Isletopathy in Type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Role of islet amyloid in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Involvement of ATP-sensitive potassium (K(ATP)) channels in the loss of beta-cell function induced by human islet amyloid polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Ultrastructure of islet microcirculation, pericytes and the islet exocrine interface in the HIP rat model of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Pancreatic pathology in non-insulin dependent diabetes (NIDDM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Introduction: organ involvement in the cardiometabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib and regression of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Diabetes research. Researchers puzzle over possible effect of Gleevec

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Remission of diabetes while on sunitinib treatment for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptor-beta increases migration of aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Genetics, pathogenesis and clinical interventions in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Review Series--Inflammation & Fibrosis. Fibrocytes and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724398

10.1517/13543784.2012.724398

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference